

BIOXIS Pharmaceutical is specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine.

Our technology is based on biomaterials scaffolds which help to regenerate tissues and improve patient outcomes and doctor's practice of medicine. BIOXIS Pharmaceutical technologies are currently focused on the aesthetic dermatology market.

PRODUCTS PIPELINE

- **MTI-12** is the first Monophasic Tissular Inductor based on ultra-pure chitosan matrix able to repair soft tissue. In 2016, MTI-12 has reached the pre-clinical stage for aesthetic indications.
- **CYTOSIAL** is a monophasic hyaluronic acid matrix with a double-level molecular organization for a longer lasting effect and a higher degree of safety. In 2016, CYTOSIAL range of dermal fillers entered into exclusive distribution agreements with distributors in Europe and Asia.

FUNDING

BIOXIS Pharmaceuticals is a French privately held company backed by its founder and a group of international investors. During its latest Series A (ended in Q1 2016) the company funded a total of €2.5M in order to finance regulatory pre-clinical trials (MTI-12) and pre-commercial launch of its HA dermal filler range CYTOSIAL.



CONTACT : Frédéric BERTAÏNA - Ceo

fbertaina@bioxis.com - 317 avenue Jean Jaures, 69007 Lyon, France

Phone +33 4 81 91 76 00 - Fax +33 4 81 91 76 01